Search results for "C2"

showing 10 items of 879 documents

A genome scan for developmental dyslexia confirms linkage to chromosome 2p11 and suggests a new locus on 7q32

2003

Developmental dyslexia is a distinct learning disability with unexpected difficulty in learning to read despite adequate intelligence, education, and environment, and normal senses. The genetic aetiology of dyslexia is heterogeneous and loci on chromosomes 2, 3, 6, 15, and 18 have been repeatedly linked to it. We have conducted a genome scan with 376 markers in 11 families with 38 dyslexic subjects ascertained in Finland. Linkage of dyslexia to the vicinity of DYX3 on 2p was confirmed with a non-parametric linkage (NPL) score of 2.55 and a lod score of 3.01 for a dominant model, and a novel locus on 7q32 close to the SPCH1 locus was suggested with an NPL score of 2.77. The SPCH1 locus has p…

MaleCandidate geneGenotypeDNA Mutational AnalysisShort ReportLocus (genetics)BiologyDyslexia03 medical and health sciences0302 clinical medicineCommunication disorderDCDC2mental disordersGeneticsmedicineHumansLanguage disorderFinlandGenetics (clinical)030304 developmental biologyGenetics0303 health sciencesGenome HumanDyslexiaChromosome MappingForkhead Transcription FactorsFOXP2medicine.diseasePedigreeRepressor ProteinsChromosomes Human Pair 2Learning disabilityFemaleLod Scoremedicine.symptomChromosomes Human Pair 7030217 neurology & neurosurgeryTranscription FactorsJournal of Medical Genetics
researchProduct

Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins

2020

Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However, the underlying mechanisms are poorly understood. This study aimed to identify cancer cachexia and soluble ACVR (sACVR) administration-evoked changes in muscle proteome. Methods Healthy and C26 tumour-bearing (TB) mice were treated with recombinant sACVR. The sACVR or PBS control were administered either prior to the tumour formation or by continued administration before and after tumour formation. Muscles were an…

MaleEXPRESSIONActivin receptor; APR; C26; Cancer cachexia; Nrk2; OXPHOSlcsh:Internal medicineCachexiaREVERSALActivin ReceptorsMETABOLISMactivin receptorOxidative PhosphorylationCell Line TumorAnimalsMuscle Skeletallcsh:RC31-1245aineenvaihduntaSerpinslihassolut318 Medical biotechnologyNrk2Cancer cachexiaMyostatinNADOXPHOSMUSCULAR-DYSTROPHYActivinsMitochondriaActivin receptorDisease Models AnimalMuscular AtrophyMICESIRTUINSOriginal ArticlesyöpätauditproteiinitC26lihassurkastumasairaudetAPRAcute-Phase Proteinscancer cachexia
researchProduct

Next-generation sequencing confirms the implication of SLC24A1 in autosomal-recessive congenital stationary night blindness.

2015

Congenital stationary night blindness (CSNB) is a clinically and genetically heterogeneous retinal disorder which represents rod photoreceptor dysfunction or signal transmission defect from photoreceptors to adjacent bipolar cells. Patients displaying photoreceptor dysfunction show a Riggs-electroretinogram (ERG) while patients with a signal transmission defect show a Schubert-Bornschein ERG. The latter group is subdivided into complete or incomplete (ic) CSNB. Only few CSNB cases with Riggs-ERG and only one family with a disease-causing variant in SLC24A1 have been reported. Whole-exome sequencing (WES) in a previously diagnosed icCSNB patient identified a homozygous nonsense variant in SL…

MaleGenes RecessiveSodium-Calcium ExchangerNight BlindnessElectroretinographyMyopiaHumansExomeGenetic Predisposition to DiseaseAmino Acid SequenceSLC24A1Family HealthHigh-throughput sequencingBase SequenceSequence Homology Amino AcidSettore MED/30 - Malattie Apparato VisivoHomozygoteHigh-Throughput Nucleotide SequencingEye Diseases HereditaryGenetic Diseases X-LinkedPedigreeNight BlindneMutationFemaleCongenital stationary night blindneHumanClinical genetics
researchProduct

A de novo heterozygous mutation in KCNC2 gene implicated in severe developmental and epileptic encephalopathy

2020

Abstract An increasing number of developmental and epileptic encephalopathies have been correlated with variants of ion channel genes, and in particular of potassium channels genes, such as KCNA1, KCNA2, KCNB1, KCNQ2, KCTD7 and KCNT1. Here we report a child with an early severe developmental and epileptic encephalopathy, spastic tetraplegia, opisthotonos attacks. The whole exome sequencing showed the de novo heterozygous variant c.1411G > C (p.Val471Leu) in the KCNC2 gene. Although this is, to our knowledge, the first case of encephalopathy associated with a KCNC2 gene variant, and further confirmatory studies are needed, previous preclinical and clinical evidence seems to suggest that KCNC…

MaleKCNC2 geneKCTD7EncephalopathyBiologyEpilepsyGeneticsmedicineHumansExomeEEGChildGeneExomeSpastic tetraplegiaGenetics (clinical)Exome sequencingGeneticsEpilepsyKv3.2ElectroencephalographyDevelopmental and epileptic encephalopathieGeneral Medicinemedicine.diseaseKCNC2Shaw Potassium ChannelsNGSMutationEuropean Journal of Medical Genetics
researchProduct

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in pat…

2013

Abstract Background This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction. Methods Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS). Results A total of 24 patients were included. F…

MaleOncologyCancer ResearchTime FactorsEsophageal NeoplasmsOrganoplatinum Compoundsmedicine.medical_treatmentMedizinKaplan-Meier EstimateDocetaxellaw.inventionRandomized controlled triallawGermanyProspective StudiesIsraelProspective cohort studyNeoadjuvant therapyChemoradiotherapyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNeoadjuvant TherapyOxaliplatinOesophagogastric cancer oxaliplatinTreatment OutcomeDocetaxelOncologyNeoadjuvant radiochemotherapyAdenocarcinomaFemaleTaxoidsEsophagogastric JunctiontherapeuticsResearch Articlemedicine.drugAdultmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsAdenocarcinomalcsh:RC254-282Disease-Free SurvivalStomach NeoplasmsInternal medicinemedicineGeneticsHumansddc:610neoplasmsAgedDose-Response Relationship Drugbusiness.industryChemoradiotherapy Adjuvantmedicine.diseasedigestive system diseasesOxaliplatinClinical trialbusinessChemoradiotherapy
researchProduct

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-s…

2010

Abstract Background The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting. Methods A Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared …

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyGuanineLung NeoplasmsCost-Benefit AnalysisPopulationDocetaxelPemetrexedlcsh:RC254-282Disease-Free SurvivalGlutamatesSurgical oncologyCarcinoma Non-Small-Cell LungCell Line TumorInternal medicineGeneticsCarcinomamedicineHumanseducationLung cancerneoplasmseducation.field_of_studybusiness.industryCarcinomaHistologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMarkov Chainsrespiratory tract diseasesQuality-adjusted life yearTreatment OutcomePemetrexedOncologyDocetaxelSpainDisease ProgressionQuality of LifeFemaleTaxoidsQuality-Adjusted Life YearsbusinessResearch Articlemedicine.drugBMC Cancer
researchProduct

Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012

2021

Abstract Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC i…

MaleOncologyCancer Researchmedicine.medical_specialtypopulation-based cancer registriesPopulationSocio-culturaleSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyCohort StudiesRisk FactorsProstateInternal medicinepopulation‐based cancer registriesmedicinethyroid cancerHumanscancer survivorsRadiology Nuclear Medicine and imagingRegistriesThyroid NeoplasmsOverdiagnosiseducationThyroid cancerResearch ArticlesRC254-282cancer survivors; Italy; population-based cancer registries; relative risk; second primary cancer; thyroid cancereducation.field_of_studycancer survivors Italy population-based cancer registries relative risk second primary cancer thyroid cancerbusiness.industryIncidenceIncidence (epidemiology)ThyroidNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerNeoplasms Second PrimaryHistory 20th Centurymedicine.diseaserelative riskmedicine.anatomical_structureOncologyItalyRelative riskFemalesecond primary cancerbusinessCancer PreventionResearch Article
researchProduct

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of …

2006

Abstract Background Elderly patients have been often excluded from or underrepresented in the study populations of combination chemotherapy trials. The primary end point of this study was to determine the response rate and the toxicity of the weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) regimen in elderly patients with advanced gastric cancer. The secondary objective was to measure the time to disease progression and the survival time. Methods Chemotherapy-naive patients with advanced gastric cancer aged 70 or older were considered eligible for study entry. Patients received weekly oxaliplatin 40 mg/m2, fluorouracil 500 mg/m2 and folinic acid 250 mg/m2. All drugs were given i…

MaleOncologymedicine.medical_specialtyCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentlcsh:RC254-282Drug Administration ScheduleLEUCOVORINFolinic acidEPI-DOXORUBICINTRACT CANCERCISPLATINADVANCED ESOPHAGOGASTRIC CANCERStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointGeneticsHumansAged6S-LEUCOVORINAged 80 and overCisplatinChemotherapybusiness.industryCombination chemotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensINFUSIONAL FLUOROURACILRANDOMIZED-TRIALOxaliplatinOxaliplatinSurvival RateRegimenOncologyFluorouracilINTENSIVE WEEKLY CHEMOTHERAPYETOPOSIDEFemaleFluorouracilbusinessResearch Articlemedicine.drug
researchProduct

The clinical significance of CDK1 expression in oral squamous cell carcinoma

2014

Objectives: To evaluate the clinical significance of cyclin-dependent kinase 1 (CDK 1 ) in 77 oral squamous cell carcinomas (OSCC) using immunohistochemical methods. Study Design: Immunohistochemical expression of CDK 1 was compared with various clinicopathological features in 77 OSCC and 60 controlled epithelia adjacent to the tumours. In addition, correlation of CDK 1 expression and prognostic and the 5-year accumulative survival rate of OSCC were investigated. Results: The CDK 1 protein was expressed in 52 cases of 77 tumor tissues (67.5%), compared with 21 cases of 60 controlled (35.0%). The expression of CDK 1 was significantly correlated with the histological grade of OSCC ( P <0.05).…

MalePathologymedicine.medical_specialtyCellOdontologíaenvironment and public healthCDC2 Protein KinaseHumansMedicineClinical significanceGeneral DentistrySurvival rateMouth neoplasmCyclin-dependent kinase 1Oral Medicine and Pathologybusiness.industryKinaseCell growthResearchMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludImmunohistochemistrySurvival Rateenzymes and coenzymes (carbohydrates)stomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellCancer researchImmunohistochemistryFemaleMouth NeoplasmsSurgerybiological phenomena cell phenomena and immunitybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space

2007

Abstract Background Prognosis after surgical therapy for pancreatic cancer is poor and has been attributed to early lymph node involvement as well as to a strong tendency of cancer cells to infiltrate into the retropancreatic tissue and to spread along the peripancreatic neural plexuses. The objective of our study was to classify the anatomical-surgical layer of the mesopancreas and to describe the surgical principles relevant for resection of the mesopancreas (RMP). Immunohistochemical investigation of the mesopancreatic-perineural lymphogenic structures was carried out with the purpose of identifying possible routes of metastatic spread. Methods Resection of the mesopancreas (RMP) was per…

MalePathologymedicine.medical_specialtymedicine.medical_treatmentlcsh:Surgerylcsh:RC254-282Sensitivity and SpecificityMesenteric VeinAnatomical spaceMesenteric VeinsPancreatectomyRisk FactorsPancreatic cancermedicineCadaverHumansNeoplasm InvasivenessLymph nodePancreasAgedAged 80 and overbusiness.industryResearchDissectionlcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePancreatic NeoplasmsDissectionmedicine.anatomical_structureLymphatic systemOncologyPancreatectomySurgeryFemalebusinessPancreasWorld Journal of Surgical Oncology
researchProduct